Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early ...

Eli Lilly (LLY) announced topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor ...

Lilly’s investigational drug met primary and key secondary endpoints in ATTAIN-2, showing significant weight loss and reduced A1c in people with obesity or overweight and type 2 diabetes.

6. Mohl JT, Shields S, Ciemins EL. Primary medication non-adherence among patients requiring long-term treatment. Presented at: AMGA Annual Conference; March 26-29, 2025; Grapevine, TX. Poster 35.

Regeneron (REGN) stock and Alnylam Pharma (ALNY) stock are in focus as their RNA therapy cemdisiran succeeds in Phase 3 trial for myasthenia gravis. Read more here.

Inside Gilead Sciences, colleagues often describe Varun Sharma as the strategist who can map a launch plan end to end, and ...

Elinzanetant successfully met the primary endpoints of the study demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (VMS, also known as ...

The primary end point (biochemical response at week 52) and key secondary end points (normalization of alkaline phosphatase at week 52, and the change from baseline in the WI-NRS score through ...

Prolonged absence from school is most harmful to achievement at the very start and in the transitional years from primary to secondary, according to new research.